Incyte Corp. recently announced that approximately 20 abstracts associated with its clinical developments will be presented at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) meetings in 2016.
The company developed the JAK1/JAK2 inhibitor, Jakafi or ruxolitinib, for the treatment of polycythemia in cases where hydroxyurea is not effective or the patient is intolerant of the medication. Jakafi can also be used to treat those at risk for myelofibrosis. Both uses have been approved by the Food and Drug Administration.
“The abstracts to be presented at ASCO and EHA illustrate both the diversity and the potential of our rich portfolio,” Incyte’s Chief Medical Officer Steven Stein said. “We are especially pleased to present long-term data from the COMFORT-I Phase 3 study, which further advances the understanding of Jakafi in the treatment of patients with myelofibrosis.”
The ASCO meeting will be taking place from June 3 to 7 in Chicago. The EHA conference will be held between June 9 and 12 in Copenhagen, Denmark.
Alerts Sign-up